Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial

Executive Summary

The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.

Advertisement

Related Content

Starts & Stops: Respicardia Puts Sleep Apnea Device PAS On Snooze
Largest Sleep Apnea Trial Backs CPAP For Improving QoL, Not For Lowering Secondary Cardio Events
Sorin Gains Distribution Rights, Minority Stake In Respicardia’s remedē Sleep Apnea Device

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register